Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 20;190(1):105-113.
doi: 10.1093/bjd/ljad317.

Hidradenitis suppurativa tarda: defining an understudied elderly population

Deveny A Y van der Weijden  1 , Nicole D K Koerts  1 , Barbara C van Munster  2 , Hessel H van der Zee  3 , Barbara Horváth  1
Affiliations

Hidradenitis suppurativa tarda: defining an understudied elderly population

Deveny A Y van der Weijden et al. Br J Dermatol. .

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic, devastating, multifactorial skin disease. Patients generally develop HS after puberty and the prevalence of the disease is assumed to decrease with higher age. Data outside the usual age range are limited, especially for elderly patients.

Objectives: To investigate the prevalence, clinical characteristics and associated comorbidities among the elderly HS population.

Methods: Data were collected through a population-wide survey-based study within the Lifelines Cohort Study in the Netherlands. The clinical characteristics of elderly patients with HS (≥ 60 years) were compared with an adult population (< 60 years) with HS. The comorbidities in elderly patients with HS were compared with those of a non-HS sex- and age-matched elderly population in a 1 : 4 ratio. HS in the elderly was defined as active HS in patients aged 60 years and older. Within the HS elderly group, two subgroups were defined, late-onset HS (HS developed after 60 years of age) and persistent HS (HS developed from a younger age but continuing after 60 years of age).

Results: Within the Lifelines cohort 209 elderly patients with HS were identified as well as an adult (< 60 years) group with HS (n = 793) and a non-HS sex- and age-matched control elderly group (n = 810). The prevalence of HS among the elderly bootstrap analysis population was 0.8% [95% confidence interval (CI) 0.4-1.2]. A significantly higher age of HS symptom onset was found compared with the adult HS group: respectively, 40 vs. 23 years (odds ratio 1.056, 95% CI 1.05-1.07). Among the elderly HS cohort (in the Discussion, the HS tarda cohort) a female : male ratio of 1.7 : 1.0 and a higher family history for HS were found. Moreover, elderly patients with HS had a significantly higher risk of having HS-associated comorbidities compared with the sex- and age-matched controls.

Conclusions: The prevalence of HS in the elderly is not rare. Among the elderly a shift from female predominance towards a lower female : male ratio in HS is observed. In addition, HS in the elderly showed significant variation in age of onset and involved body areas. Moreover, elderly patients with HS were more susceptible to multimorbidity. Finally, we propose defining HS in the elderly as 'HS tarda' and subdividing it as late-onset and persistent HS tarda.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest D.v.d.W., N.D.K.K. and B.C.v.M. report no conflicts of interest. H.H.v.d.Z. reports fees (advisory boards, consultations) from AbbVie, InflaRX, Insmed, Novartis Pharma and UCB Pharma. B.H. reports fees (paid to the institution) for the following: advisory boards, consultations, educational grants and investigator initiative studies from AbbVie and Janssen-Cilag; advisory boards, consultations and investigator initiative studies from Novartis Pharma; advisory boards and consultations from UCB Pharma; consultations and investigator initiative studies from Akari Therapeutics and Celgene; consultations from LEO Pharma, Philips, Regeneron, Roche and Sanofi; and investigator initiative studies from Solenne B.V.

Comment in

References